Prosecution Insights
Last updated: November 04, 2026
Application No. 18/223,962

Nano-structural Protein Degradation Tool, Use, and Preparation Method thereof, and Lipid-based Protein Degradation Tool, Use, and Preparation Method thereof

Final Rejection §102§103
Filed
Jul 19, 2023
Priority
Jul 29, 2022 — CN 2022109118535 +1 more
Examiner
PACKARD, BENJAMIN J
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Henan University
OA Round
2 (Final)
67%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
908 granted / 1356 resolved
+7.0% vs TC avg
Strong +15% interview lift
Without
With
+15.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
53 currently pending
Career history
1417
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
48.2%
+8.2% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
15.8%
-24.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1356 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed 9/10/2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 102 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 9, 18, 20, 21, and 23 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Davis (CA 2771564 A1). Davis discloses a method of treating a patient suffering from a tumor by administering nanoparticles, where a monoclonal antibody is linked to the nanoparticle via a polymer (claims 23 and 27). Examiner notes that while the instant claims include multiple generic terms, the core of the claims is administration of an antibody (POI recognition group) via a polymer linker to a nanoparticle (third degradation tool) for the treatment of tumors (a disease of abnormal protein accumulation). Where the linker is a polymer, it should be hydrophilic, hydrophobic, or amphiphilic and 0-1000kDa, which are also disclosed by Davis based on the size of the nanoparticles (pg 12, lines 4-7). The nanoparticle also needs to be hydrophilic, hydrophobic, or inorganic. The composition is administered via injection (pg 72, line 25). Administration is between 0.1 mg/kg and 100 mg/kg Claim Rejections - 35 USC § 103 Claims 9, 18, 20, 21, and 23 are rejected under 35 U.S.C. 103 as being unpatentable over Davis (CA 2771564 A1). Davis appears to be anticipatory as discussed above, but for sake of completeness of record, it is also rejected as obvious. It would have been obvious to formulate a nanoparticle with a hydrophobic linker to the antibody, and then to treat a patient with a tumor with the resulting nanoparticles. Additionally, it would be obvious to vary the length of the linker to optimize delivery while retaining pharmacokinetic properties. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN J PACKARD whose telephone number is (571)270-3440. The examiner can normally be reached Mon 2-6pm and Tues-Fri 9:30am-6:30pm + mid-day flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BENJAMIN J PACKARD/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Jul 19, 2023
Application Filed
Apr 09, 2026
Non-Final Rejection mailed — §102, §103
Jul 09, 2026
Response Filed
Oct 07, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778174
COMPOSITIONS FOR USE IN THE REDUCTION OF NOCICEPTION AND OTHER HEALTH BENEFITS IN INFANTS AND YOUNG CHILDREN
4y 4m to grant Granted Nov 03, 2026
Patent 12782339
SYNTHESIS AND USE OF N-BENZYL SULFONAMIDES
3y 9m to grant Granted Nov 03, 2026
Patent 12779056
AGENT FOR DETECTING INTERACTION BETWEEN TISSUES AND ORGANS
3y 6m to grant Granted Nov 03, 2026
Patent 12778862
STABLE BIOACTIVE GLASS FORMULATIONS
2y 6m to grant Granted Nov 03, 2026
Patent 12778892
RADIOPROTECTIVE COMPOSITIONS AND METHODS FOR PREPARATION THEREOF
1y 12m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
67%
Grant Probability
82%
With Interview (+15.3%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1356 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month